Literature DB >> 8310505

Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone.

H L Rilo1, P B Carroll, Y J Zeng, P Fontes, J Demetris, C Ricordi.   

Abstract

A topic of current interest in islet transplantation is the selection of an optimal site for long-term graft survival since the intrahepatic site may be characterized by long-term failure. Additionally, the use of immunosuppressive agents such as prednisone may adversely affect long-term graft function. In this study, we examined the long-term outcome of intrahepatic canine islet autografts and compared this with results obtained in animals treated with a short-term course of steroids or steroids plus insulin. Islets were isolated using the automated method and were purified on discontinuous Euro-Collins Ficoll gradients (densities: 1.108, 1.096, 1.037). Prednisone-treated dogs were hyperglycemic during treatment but returned to normoglycemia after steroid withdrawal. Control and insulin-treated animals were normoglycemic following autotransplant, with no difference in plasma glucose levels between controls and the insulin-treated animals. All control dogs became diabetic at 11, 14, 17, and 19 months following islet autograft. Prednisone-treated dogs had more rapid onset of diabetes at 7, 11, and 12 months following ITx. Prednisone-treated dogs given insulin became hyperglycemic at 10, 14, 18, and 19 months post ITx. Graft failure was preceded by a decline in IVGTT Kg values and diminished insulin secretion. At the time of graft failure islets showed no lymphocytic infiltration and islets stained positive for glucagon but few insulin-containing cells were seen. Thus, even when an initially adequate B cell mass was transplanted, the intrahepatic site was characterized by long-term canine autograft failure. A short course of prednisone accelerated the time to graft failure and insulin treatment reversed this acceleration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8310505     DOI: 10.1097/00007890-199401001-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Deterioration of glycemic control after corticosteroid administration in islet autotransplant recipients: a cautionary tale.

Authors:  Anh Ngo; David E R Sutherland; Gregory J Beilman; Melena D Bellin
Journal:  Acta Diabetol       Date:  2011-08-07       Impact factor: 4.280

2.  Remission of digestive insufficiency by islet transplantation to the pancreas.

Authors:  John I Stagner; Horacio L Rilo; Karen Wyler
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

Review 3.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Autologous islet transplantation to prevent diabetes after pancreatic resection.

Authors:  D C Wahoff; B E Papalois; J S Najarian; D M Kendall; A C Farney; J P Leone; J Jessurun; D L Dunn; R P Robertson; D E Sutherland
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

5.  Total pancreatectomy and autologous islet cell transplantation as a means to treat severe chronic pancreatitis.

Authors:  Horacio L Rodriguez Rilo; Syed A Ahmad; David D'Alessio; Yasuhiro Iwanaga; Joseph Kim; Kyuran A Choe; Jonathan S Moulton; Jill Martin; Linda J Pennington; Debbie A Soldano; Jamie Biliter; Steve P Martin; Charles D Ulrich; Lehel Somogyi; Jeffrey Welge; Jeffrey B Matthews; Andrew M Lowy
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.